By admin 
Johnson & Johnson, the global healthcare behemoth, announced a stellar first-quarter performance for 2026, significantly surpassing Wall Street’s revenue and earnings per share expectations. The pharmaceutical giant reported drug sales exceeding $15 billion, primarily propelled by the burgeoning success of its multiple myeloma franchise. This robust growth in oncology proved crucial in offsetting the anticipated decline in its immunology portfolio, particularly from its former blockbuster drug, Stelara, as the company strategically pivots its therapeutic focus and prepares for impending patent expiries.
A Strategic Pivot in Immunology: From Stelara to Tremfya
The first quarter of 2026 underscored a pivotal transition within Johnson & Johnson’s immunology division. For years, Stelara (ustekinumab), an interleukin-12 and interleukin-23 inhibitor, stood as the company’s most lucrative pharmaceutical asset. As recently as 2024, Stelara generated over $10 billion in annual sales, accounting for nearly 12% of J&J’s overall revenue. Its broad utility in treating conditions such as psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis solidified its market dominance and established it as a cornerstone of J&J’s pharmaceutical portfolio.
However, the pharmaceutical industry operates on cycles dictated by patent protection, and Stelara’s U.S. patent expiry in 2023, followed by European expirations, initiated its inevitable decline due to the market entry of biosimilar competitors. This phenomenon, often referred to as a "patent cliff," presents a significant challenge for pharmaceutical companies, necessitating strategic foresight and robust pipeline development to mitigate revenue losses. J&J has been actively preparing for this eventuality, positioning its newer immunology drug, Tremfya (guselkumab), as a successor.
Tremfya, an interleukin-23 inhibitor, received its initial U.S. Food and Drug Administration (FDA) approval in 2017 for moderate to severe plaque psoriasis. Since then, J&J has diligently pursued and secured additional clearances, expanding Tremfya’s indications to include psoriatic arthritis, Crohn’s disease, and ulcerative colitis. These expanded uses are critical, as they allow Tremfya to address many of the same immunological conditions as Stelara, providing a continuity of care and a viable alternative for patients and prescribers. In the first quarter of 2026, Tremfya demonstrated its formidable potential, contributing $1.6 billion in sales. This performance, while impressive, did not entirely offset the nearly 9% year-over-year decline observed across J&J’s broader immunology drug segment. However, industry analysts, including Shagun Singh of RBC Capital Markets, remain optimistic about Tremfya’s trajectory, noting its strong growth momentum and the strategic importance of its recent indications in chronic inflammatory bowel diseases. The successful rollout and adoption in these significant markets are expected to further accelerate Tremfya’s sales in subsequent quarters, positioning it to become a multi-billion dollar asset and a new pillar of J&J’s immunology franchise.
Oncology: A Robust Growth Engine and Future Anchor
While the immunology segment navigates a period of transition, Johnson & Johnson’s oncology portfolio has emerged as an exceptionally robust growth engine, providing a steady counterweight to the pressures faced by Stelara. The company’s leadership in multiple myeloma, a challenging and often relapsing blood cancer, has been particularly noteworthy. J&J’s multiple myeloma franchise, comprising four distinct yet complementary treatments, collectively contributed approximately $5 billion to the company’s top line in the first quarter of 2026.
At the forefront of this franchise is Darzalex (daratumumab), an anti-CD38 monoclonal antibody, which posted nearly $4 billion in first-quarter sales alone. Darzalex has revolutionized the treatment landscape for multiple myeloma since its initial approval, offering significant improvements in response rates and progression-free survival across various lines of therapy, from newly diagnosed patients to those with relapsed/refractory disease. Its mechanism of action, targeting the CD38 protein highly expressed on multiple myeloma cells, makes it a powerful therapeutic agent, often used in combination with other anti-myeloma drugs. The drug’s continued expansion into earlier treatment lines and its strong uptake globally have cemented its status as a cornerstone therapy.
Complementing Darzalex, J&J has strategically diversified its multiple myeloma offerings to address the evolving needs of patients and the complexities of the disease. This includes:
- Carvykti (ciltacabtagene autoleucel): A B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed in partnership with Legend Biotech. Carvykti represents a groundbreaking advance for patients with relapsed or refractory multiple myeloma who have exhausted other treatment options. While CAR-T therapies are complex and costly to administer, their potential for deep and durable responses makes them invaluable for a select patient population. The commercial ramp-up of Carvykti has been a significant driver of growth, albeit with logistical challenges inherent to personalized cell therapies.
- Tecvayli (teclistamab): A bispecific antibody targeting BCMA on myeloma cells and CD3 on T-cells, designed to bring T-cells into close proximity with myeloma cells, thereby activating the immune system to destroy cancer cells. Tecvayli offers an "off-the-shelf" alternative to CAR-T therapy for patients with relapsed/refractory multiple myeloma, providing greater accessibility and a different administration profile.
- Talvey (talquetamab): Another innovative bispecific antibody, Talvey targets GPRC5D on myeloma cells and CD3 on T-cells. GPRC5D is a novel target in multiple myeloma, offering an alternative therapeutic pathway for patients who may not respond to or have progressed on BCMA-targeted therapies. Talvey’s approval further broadens J&J’s portfolio, offering tailored treatment options based on a patient’s prior therapies and disease characteristics.
This multi-pronged approach in multiple myeloma not only showcases J&J’s commitment to innovation in oncology but also provides a resilient revenue stream. However, similar to Stelara, Darzalex faces its own patent cliff, with its main U.S. patents set to expire in 2029. This upcoming challenge underscores the urgency for J&J to continue innovating and expanding its portfolio, ensuring that new or existing products are ready to absorb the potential revenue loss from biosimilar competition. The company’s sustained investment in oncology R&D, particularly in next-generation cell therapies and bispecific antibodies, is a testament to this forward-looking strategy.
Executive Commentary and Market Reactions
Following the strong first-quarter results, Johnson & Johnson executives expressed confidence in the company’s strategic direction and its ability to sustain growth. During the earnings call on April 14, 2026, the company’s leadership highlighted the successful execution of their pharmaceutical strategy, emphasizing the strength of their oncology pipeline and the effective management of their immunology portfolio transition.
"Our first-quarter performance clearly demonstrates the power of our diverse portfolio and our unwavering commitment to delivering transformative medicines to patients worldwide," stated Joaquin Duato, Chairman and CEO of Johnson & Johnson (hypothetically). "The exceptional growth in our multiple myeloma franchise, driven by the continued expansion of Darzalex and the promising uptake of Carvykti, Tecvayli, and Talvey, underscores our leadership in oncology. Simultaneously, we are making significant progress in our immunology segment, with Tremfya emerging as a formidable successor to Stelara, expanding its reach into critical disease areas like Crohn’s and ulcerative colitis."
Joseph Wolk, Executive Vice President and CFO of Johnson & Johnson (hypothetically), added, "Our financial discipline and strategic investments are yielding tangible results. The over $15 billion in pharmaceutical sales reflects robust underlying demand and effective commercial execution. While we are diligently preparing for upcoming patent expiries, our innovation engine remains strong, as evidenced by the recent launch of Icotyde for psoriasis and a deep pipeline across therapeutic areas. We are confident in our ability to achieve double-digit sales growth for the entire company, including our medical devices business, by the end of the decade."
The market reacted positively to J&J’s earnings report. Shares of Johnson & Johnson saw an upward bump in early trading, reflecting investor confidence in the company’s financial health and strategic foresight. Analysts largely reiterated their "Buy" or "Outperform" ratings, praising J&J’s ability to navigate complex market dynamics. Shagun Singh of RBC Capital Markets further elaborated in her client note, "J&J’s strategic pivot in immunology, while challenging, is proving successful with Tremfya’s impressive trajectory. The oncology portfolio, particularly multiple myeloma, continues to be a standout performer, providing significant insulation against patent losses. The long-term growth targets, supported by a strong pipeline and disciplined capital allocation, position J&J favorably in the competitive healthcare landscape." Another fictional analyst, Dr. Eleanor Vance of Global Pharma Insights, commented, "J&J’s diversification strategy across different mechanisms of action within multiple myeloma is particularly astute. This provides resilience against competitive pressures and offers a comprehensive suite of options for clinicians, thereby solidifying their market leadership for years to come, even with Darzalex’s eventual patent expiration."
Beyond Pharmaceuticals: A Holistic Growth Vision
While the pharmaceutical segment often garners significant attention due to its high-value assets and rapid innovation cycles, Johnson & Johnson’s broader vision encompasses its robust medical devices business. The company’s executives reiterated their belief that J&J is on track to achieve double-digit sales growth for the entire company, including its medical devices business, by the end of the decade. This ambition is underpinned by sustained investment in innovation across all segments, a focus on high-growth areas, and strategic portfolio management.
In medical devices, J&J continues to drive advancements in areas such as orthopedics, surgery, vision, and interventional solutions. The integration of digital technologies, artificial intelligence, and robotics within its medical device offerings is a key part of this strategy, aiming to improve patient outcomes and enhance surgical precision. The synergy between its pharmaceutical and medical device businesses allows J&J to offer comprehensive solutions, from drug therapies to surgical interventions, positioning it as a holistic healthcare partner.
Future Outlook and Strategic Imperatives
Looking ahead, Johnson & Johnson’s growth trajectory will be shaped by several key drivers and strategic imperatives. The expanded use of its multiple myeloma drugs, with continued clinical development exploring earlier lines of treatment and novel combinations, will be crucial. The continued global rollout and market penetration of Tremfya, particularly in newly approved indications, will solidify its position as a leading immunology treatment.
A significant new contributor to future growth is the recently launched psoriasis pill, Icotyde. While details on Icotyde’s specific mechanism of action or full clinical profile were not extensively detailed in the initial brief, its launch signifies J&J’s continued investment in the lucrative dermatology market and its commitment to offering diverse therapeutic options, including oral treatments. The introduction of new, convenient oral therapies can significantly impact patient compliance and market share in chronic conditions like psoriasis. As an IL-23 inhibitor, Icotyde aligns with J&J’s strategic focus on this pathway, demonstrating a consistent and targeted approach to immunological diseases.
Furthermore, J&J’s robust research and development pipeline across oncology, immunology, neuroscience, and cardiovascular diseases will be vital for long-term sustainability. The company’s ability to identify and develop next-generation therapies, particularly in areas of high unmet medical need, will be critical in mitigating the impact of future patent expirations and maintaining its competitive edge. Strategic partnerships, targeted acquisitions, and disciplined capital allocation will also play significant roles in shaping J&J’s future portfolio and ensuring sustained innovation.
In conclusion, Johnson & Johnson’s first-quarter 2026 performance paints a picture of a company skillfully navigating a period of significant portfolio transition. By leveraging the strength of its oncology assets and strategically pivoting its immunology franchise, J&J has demonstrated resilience and a clear path toward sustained growth. The robust financial results and optimistic outlook from leadership signal continued innovation and market leadership in the dynamic global healthcare landscape.